Genmab nine-month operating profit falls to $986 million; revenue rises 22% to $3.24 billion

Bitget2026/11/05 16:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab’s operating profit fell to USD 986 million in the first nine months of 2026.
Revenue rose 22% to USD 3.24 billion, helped by higher DARZALEX and Kesimpta royalties.
Operating expenses climbed 35% to USD 2.02 billion.
October brought positive Phase 3 topline results for epcoritamab, Rina-S and petosemtamab, supporting plans to engage regulators.
Genmab maintained its 2026 financial guidance published August 6.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051101PRIMZONEFULLFEED1001302074) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab nine-month operating profit falls to $986 million; revenue rises 22% to $3.24 billion

You may also like

Crypto prices